Hairy Cell Leukemia Related Osteolyses Detected by PET Successfully Treated with Cladribine and Ibandronate

IF 2.2 4区计算机科学 Q3 COMPUTER SCIENCE, INFORMATION SYSTEMS

ACM Sigcomm Computer Communication Review Pub Date : 2020-11-28 DOI:10.46527/2582-5038.170

E. Ranković, A. Balenović, S. Dotlic, I. Aurer

引用次数: 0

Abstract

Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disorder clinically characterized by pancytopenia and splenomegaly [1], with high overall survival rates after treatment with purine analogues [2-4]. We report a relatively young patient with HCL presenting with widespread osteolytic disease detected by PET who was successfully treated with cladribine and ibandronate. Osteolyses are not considered a frequent complication of HCL [5] and we are aware of only one case report describing the use of PET for diagnostic purposes in this setting [6]. Resolution of bone lesions has been described after treatment with radiotherapy or cladribine [6-9], but to our knowledge, there are no data on the use of bisphosphonates in this context.

查看原文本刊更多论文

氯德里滨联合依班膦酸盐成功治疗毛细胞白血病相关骨溶解

毛细胞白血病（HCL）是一种罕见的惰性淋巴增生性疾病，临床特征为全血细胞减少症和脾肿大[1]，嘌呤类似物治疗后总生存率高[2-4]。我们报告了一名相对年轻的HCL患者，其PET检测到广泛的溶骨性疾病，并成功地用克拉屈滨和伊班膦酸盐治疗。溶骨细胞不被认为是HCL的常见并发症[5]，据我们所知，只有一份病例报告描述了在这种情况下使用PET进行诊断[6]。已经描述了在放疗或克拉屈滨治疗后骨损伤的解决[6-9]，但据我们所知，没有关于在这种情况下使用双磷酸盐的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACM Sigcomm Computer Communication Review 工程技术-计算机：信息系统

CiteScore

6.90

自引率

3.60%

发文量

审稿时长

4-8 weeks

期刊介绍： Computer Communication Review (CCR) is an online publication of the ACM Special Interest Group on Data Communication (SIGCOMM) and publishes articles on topics within the SIG''s field of interest. Technical papers accepted to CCR typically report on practical advances or the practical applications of theoretical advances. CCR serves as a forum for interesting and novel ideas at an early stage in their development. The focus is on timely dissemination of new ideas that may help trigger additional investigations. While the innovation and timeliness are the major criteria for its acceptance, technical robustness and readability will also be considered in the review process. We particularly encourage papers with early evaluation or feasibility studies.